Clinical Trial Update: S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial (S0536) evaluated the combination of cetuximab, paclitaxel, carboplatin, and bevacizumab in patients with advanced non-small cell lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Adenosquamous Cell Lung Cancer
• Large Cell Lung Cancer
• Non-small Cell Lung Cancer
• Squamous Cell Lung Cancer
• Stage Iiib Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• ERBITUX (cetuximab)
• Paraplatin (Carboplatin)
• Taxol (paclitaxel)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-09-14